[4-(2,4-二氯苯基)嘧啶-2-基]胺 | 828273-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: [4-(2,4-二氯苯基)嘧啶-2-基]胺
• 中文别名: 4-(2,4-二氯苯基)-2-氨基嘧啶
• 英文名称: 4-(2,4-dichlorophenyl)pyrimidin-2-amine
• 英文别名: 4-(2,4-dichloro-phenyl)-pyrimidin-2-ylamine
• CAS: 828273-03-6
• 化学式: C₁₀H₇Cl₂N₃
• mdl: MFCD04050240
• 分子量: 240.092
• InChiKey: IIQPBSILLIMQBY-UHFFFAOYSA-N

物化性质

• 沸点：
  432.3±53.0 °C(Predicted)
• 密度：
  1.434±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

文献信息

• Pyrimidine Derivatives As HSP90 Inhibitors
  申请人：Chessari Gianni

  公开号：US20090215777A1

  公开（公告）日：2009-08-27

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR 3 ; R 1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R 10 ; and R 2 , R 3 and R 10 are as defined in the claims.

  该发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式（I）：或其盐、互变异构体、溶剂合物或N-氧化物；其中：A为N或CR基团；R1为由5至10个环成员组成的单环或双环碳环或杂环，其中最多两个环成员可以是从N、O和S中选择的杂原子，其余为碳原子，碳环或杂环可以选择地被一个或多个取代基独立地选择自R10的取代基取代；而R2、R3和R10如权利要求中所定义。
• PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP2049497A2

  公开（公告）日：2009-04-22
• CRYSTALLINE CDC7 INHIBITOR SALTS
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2499128A1

  公开（公告）日：2012-09-19
• Diagnostic Agent For Ischemic Heart Disease Risk Group
  申请人：Daimon Masao

  公开号：US20080146498A1

  公开（公告）日：2008-06-19

  The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.
• US8658662B2
  申请人：——

  公开号：US8658662B2

  公开（公告）日：2014-02-25